CD47-一种新的预后预测器在上皮卵巢癌和与临床病理学和基因突变特征的相关性和相关性

相关实验视频

Updated: Aug 3, 2026

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Xukai Luo¹, Jiahang Mo², Min Zhang¹

¹Department of Gynecological Oncology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.

World journal of surgical oncology

|February 5, 2024

概括

在上皮卵巢癌 (EOC) 中CD47的高表达与预后较差和瘤特征的攻击性有关. 使用CD47,CA125和BRCA突变的新风险模型可以帮助识别高风险的EOC患者.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
生物标志物发现发现

背景情况:

表皮卵巢癌 (EOC) 具有较差的免疫原性,限制了免疫治疗的有效性.
确定预后生物标志物对于分层EOC患者和量身定制治疗至关重要.
CD47在EOC预后中的作用及其遗传相关性仍然不清楚.

研究的目的:

为了研究CD47在EOC中的预后意义.
探索CD47表达与EOC的生物行为和遗传特征之间的相关性.
开发一个用于EOC预后的预测模型.

主要方法:

免疫组织化学 (IHC) 和下一代测序 (NGS) 用于分析75个EOC组织样本中的CD47,PD-L1和突变.
临床病理学和基因组特征与CD47表达相关.
卡普兰-梅尔,考克斯回归,风险得分建模和名图分析被用来评估预后因素和模型预测能力.

主要成果:

高CD47表达 (63.7%) 与高级FIGO阶段,升高的CA125/HE4,瘤,淋巴结转移,更高的Ki-67,抗性以及BRCA,HRD和TP53.3中的突变有关.
高CD47表达与明显更糟糕的EOC预后相关.
CA125,CD47和BRCA突变被确定为独立的预后因素.
一个风险评分模型和名图 (一致性指数:0.777) 有效预测了EOC患者的结果.

结论:

CD47与EOC的恶性生物学和遗传特征有显著的关联.
CD47在EOC瘤微环境中发挥着多方面的作用.
结合CD47,CA125和BRCA突变的可靠预测模型可以帮助管理高风险的EOC种群.

关键词:

生物标志物生物标志物 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 CD47 卵巢上皮癌是卵巢癌的表皮癌.免疫治疗是一种免疫疗法.这个名字叫做Nomogram.

更多相关视频

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...